Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing

Regulatory win is real, but commercial payoff and financials remain unproven and opaque.

What the company is saying

Vivos Inc. is positioning its receipt of the State of Washington Radioactive Materials License as a pivotal achievement, framing it as a 'significant regulatory milestone' for its animal health division. The company wants investors to believe that this approval unlocks the next phase of growth, enabling in-house production of IsoPet® at its new domestic manufacturing facility in Richland, Washington. The announcement repeatedly emphasizes the ability to 'scale production' and meet 'growing demand' from veterinarians and pet owners, using language that suggests imminent commercial expansion. However, the company provides no quantitative evidence for demand, production capacity, or sales, instead relying on broad claims of 'strong interest and adoption growth.' The tone is upbeat and confident, projecting a sense of momentum and inevitability, but it is not matched by hard data or specifics on execution. Management, including CEO Mike Korenko, COO David Swanberg, and President Brad Weeks, are named, but the announcement does not highlight any external validation or participation from notable third parties, such as institutional investors or strategic partners. The narrative fits a classic biotech playbook: regulatory progress is presented as a proxy for commercial readiness, even though the actual path to revenue remains undefined. Compared to prior communications (which are not available for reference), there is no evidence of a shift in messaging, but the focus on regulatory achievement over financial or operational metrics is clear. The company buries or omits entirely any discussion of costs, funding needs, or the specific hurdles remaining before IsoPet® or RadioGel® generate meaningful revenue.

What the data suggests

The only concrete data disclosed is the receipt of the State of Washington Radioactive Materials License for IsoPet® manufacturing, dated June 11, 2026, and the location of the new facility at the Applied Process Engineering Laboratory in Richland, Washington. There are no financial figures—no revenue, no expenses, no cash flow, no production volumes, and no sales orders—provided in the announcement. This absence of financial disclosure makes it impossible to assess the company’s financial trajectory, profitability, or even basic operational scale. The gap between the company’s claims of 'scaling production' and 'growing demand' and the actual evidence is stark: there are no metrics to support these assertions. There is also no information on whether prior targets or guidance have been met or missed, as no historical data or benchmarks are referenced. The quality of disclosure is poor from a financial analysis perspective, as key metrics are missing and there is no way to compare performance over time or against peers. An independent analyst, looking only at the numbers (or lack thereof), would conclude that while the regulatory milestone is real, the commercial and financial implications are entirely speculative at this stage. The announcement is operationally significant but financially opaque.

Analysis

The announcement highlights a genuine regulatory milestone—the receipt of a State of Washington Radioactive Materials License for IsoPet® manufacturing—which is a realised, factual event. However, much of the narrative is forward-looking, referencing anticipated production, future clinical trials, and expansion of treatment centers, none of which are supported by numerical evidence or binding agreements. The language inflates the significance of the milestone by implying imminent commercial and clinical impact, yet provides no data on production volumes, sales, or financial outcomes. The mention of a new manufacturing facility signals capital intensity, but there is no disclosure of costs, funding, or immediate earnings impact. The gap between narrative and evidence is moderate: the license is a necessary step, but the benefits are not yet realised and timelines are vague. The announcement would be stronger if it included concrete metrics on production, sales, or signed clinical trial agreements.

Risk flags

• ●Operational execution risk is high: while the company has secured a regulatory license, there is no evidence it has the operational capacity, supply chain, or quality controls in place to reliably manufacture and distribute IsoPet® at scale. This matters because regulatory approval is only the first step; failure to execute on production or distribution would render the license commercially meaningless.
• ●Financial opacity is a major concern: the announcement contains no financial data—no revenue, no costs, no cash position, and no guidance. For investors, this means there is no way to assess the company’s burn rate, funding needs, or path to profitability, increasing the risk of unexpected dilution or insolvency.
• ●Forward-looking statements dominate: the majority of the company’s claims relate to future production, clinical trials, and market expansion, none of which are supported by binding agreements, customer orders, or disclosed timelines. This pattern is a classic red flag for execution risk and potential over-promising.
• ●Capital intensity is flagged by the mention of a new domestic manufacturing facility, but there is no disclosure of the capital required, how it was funded, or whether additional financing will be needed. High capital intensity with unclear funding sources can lead to future dilution or debt.
• ●Disclosure quality is poor: the company omits key facts such as production capacity, sales pipeline, or even the number of treatment centers. This lack of transparency makes it difficult for investors to perform due diligence or compare the company to peers.
• ●Timeline risk is significant: with no concrete dates for production, clinical trials, or commercial rollout, investors face the risk that milestones will be delayed or never realised. The phrase 'in the near future' is too vague to be actionable.
• ●No external validation: the announcement does not mention any partnerships, customer contracts, or third-party endorsements, which would provide independent confirmation of demand or operational readiness. The absence of such validation increases the risk that the company’s narrative is aspirational rather than grounded in market reality.
• ●Geographic and regulatory complexity: while the company is focused on the United States and specifically Washington State, any expansion into other states or internationally will require additional regulatory approvals, which can be time-consuming and costly. This adds another layer of execution risk that is not addressed in the announcement.

Bottom line

For investors, this announcement confirms that Vivos Inc. (OTCQB:RDGL) has achieved a real regulatory milestone by securing a State of Washington Radioactive Materials License for IsoPet® manufacturing. However, the practical impact of this milestone is limited by the absence of any disclosed financials, production metrics, or evidence of commercial traction. The company’s narrative is credible only insofar as the license is a necessary precondition for manufacturing, but all claims about scaling, demand, and clinical trial support remain unsubstantiated. No notable institutional figures or external partners are mentioned, so there is no independent validation of the company’s prospects or market interest. To change this assessment, the company would need to disclose concrete data: production volumes, sales orders, signed clinical trial agreements, or financial commitments. In the next reporting period, investors should watch for hard metrics—actual shipments, revenue recognition, customer contracts, and progress on the RadioGel® amendment. At this stage, the signal is worth monitoring but not acting on; the regulatory win is necessary but not sufficient for commercial success. The most important takeaway is that while the company has cleared a regulatory hurdle, the path to revenue and profitability remains entirely unproven and highly uncertain.

Announcement summary

(OTCQB: RDGL) Vivos Inc. announced that it has received its State of Washington Radioactive Materials License for the manufacturing of IsoPet ®. This approval allows for in-house production of IsoPet ® at Vivos’ new domestic manufacturing facility located at the Applied Process Engineering Laboratory (APEL) in Richland, Washington. The license enables Vivos to establish reliable, compliant domestic manufacturing capabilities and scale production to meet growing demand from veterinarians and pet owners across the country. Vivos will immediately apply for an amendment to add RadioGel ® to the license, which will support clinical trials in the United States and internationally. The company anticipates shipping its first production run in the near future. IsoPet ® delivers a high therapeutic dose of Yttrium-90 directly into the tumor, providing a precise, effective treatment option with minimal impact on surrounding healthy tissue. The company continues to see strong interest and adoption growth in its animal therapy division.

Disagree with this article?